Fig. 1: Flow cytometric findings of PD-1 (CD279), ICOS (CD278), and CXCR5 (CD185) expression in non-neoplastic T-cells and T-cell lymphoma. | Blood Cancer Journal

Fig. 1: Flow cytometric findings of PD-1 (CD279), ICOS (CD278), and CXCR5 (CD185) expression in non-neoplastic T-cells and T-cell lymphoma.

From: Bright PD-1 expression by flow cytometry is a powerful tool for diagnosis and monitoring of angioimmunoblastic T-cell lymphoma

Fig. 1

Non-neoplastic T-cell population with bright PD-1 expression in reactive lymph node (green arrow) shows co-expression of ICOS and CXCR5 (a–c). Non-neoplastic T-cell population with bright PD-1 expression in lymph node with follicular lymphoma (red arrow) shows co-expression of ICOS and CXCR5 (d–f). Abnormal CD4-positive T-cell population with loss of surface CD3 identified in lymph node with AITL (g, black arrow; Case 11). This abnormal T-cell population shows bright PD-1 expression (h). This population also co-express ICOS and CXCR5 (i, CD185 plot not shown). PD-1 mean fluorescent intensity (MFI) in tissue sample. MFI in AITL is significantly higher than that of non-AITL PTCL (j). Receiver Operating Characteristic (ROC) Curve of PD-1 MFI in tissue sample shows high sensitivity and specificity observed in this assay differentiating AITL from other PTCL (p < 0.001, AUC 0.978: sensitivity 93.15% and specificity 92.86% for a cutoff of MFI 1560.64) (k). PD-1 mean fluorescent intensity (MFI) in peripheral blood sample. MFI in AITL is significantly higher than that of non-AITL PTCL (l). ROC curve of PD-1 MFI in peripheral blood sample also shows high sensitivity and specificity in differentiating AITL from other PTCL (p < 0.001, AUC 0.986: sensitivity 93.75% and specificity 95.45% for a cutoff of MFI 836.33) (m).

Back to article page